Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Even the government has plumbing problems

Executive Summary

"As soon as they put it in front of me to sign," Office of New Drugs Director John Jenkins says, he will sign a memorandum of agreement setting out the duties of OND and Office of Safety and Epidemiology staff in reviewing safety issues for new drugs. A scheduled June 16 signing of the memo by Jenkins and OSE Director Gerald Dal Pan was delayed when a broken water main closed some FDA offices. Personnel in the two offices already are operating under the new procedures, the two assured those attending a June 26 town hall meeting during the Drug Information Association meeting in Boston. If staff cannot resolve their differences, the agreement calls for passing decisions up to the two office directors and then to CDER Director Janet Woodcock, if necessary. The latter will be a "rare occurrence," Jenkins and Dal Pan insist

You may also be interested in...



FDA Drug Review, Surveillance Offices Agree To Share Safety Authority

FDA's drug review and drug safety offices have set aside their differences and laid out an agreement that more equally divides regulatory authority on issues related to drug safety

State Agencies Sharpen Supplement Market Oversight During Pandemic, With Industry's Thanks

"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III.  He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.

Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration

In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments. 

UsernamePublicRestriction

Register

PS049811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel